📢 [NEW] IN VITRO HFpEF MODEL – ACCELERATING HEART FAILURE DRUG DISCOVERY

This model was designed by PhysioStim’s research team, leveraging strong expertise in cardiometabolic diseases and human stem cell–based technologies to advance preclinical cardiovascular research.

PhysioStim Launches a Unique In Vitro HFpEF Model to Advance Cardiometabolic Drug Discovery

DOWNLOAD OUR MODEL

DOWNLOAD OUR WHITE PAPER

Last News

📢 [NEW] WHITE PAPER - HEART FAILURE: THE URGENT NEED TO INNOVATE

This review was authored by Bruno Le Grand (PhD), whose deep expertise in cardiovascular pharmacology and extensive experience in the pharmaceutical industry bring both rigor and insight to this work.

Mar 27, 2026

Events

PhysioStim at EUROTOX 2025 – Meet us in Athens!

PhysioStim is proud to take part in EUROTOX 2025, the 59th Congress of the European Societies of Toxicology, as an exhibitor and poster presenter.

Sep 14, 2025 - Sep 17, 2025

PhysioStim at 2025 SPS Annual Meeting – Meet us in Netherlands!

PhysioStim is pleased to participate in the 2025 Safety Pharmacology Society (SPS) Annual Meeting, the premier global event for safety pharmacology professionals.

Oct 13, 2025 - Oct 15, 2025

Tags/Categories

Model